Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Hemangioma 9Hemangioma, Capillary 7Melanoma 6Breast Neoplasms 5Carcinoma, Hepatocellular 4Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Hypertension, Portal 3Hemangiosarcoma 3Fallopian Tube Neoplasms 3Urinary Bladder Neoplasms 2Sarcoma, Kaposi 2Ovarian Neoplasms 2Hemangioma, Cavernous, Central Nervous System 2Colorectal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Ulcer 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Spinal Cord Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1

Interventions

Propranolol 2daratumumab 1Watchful Waiting 1Surgical Procedures, Operative 1Simvastatin 1Observation 1DNA 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hemangioma, Cavernous, Central Nervous System × Propranolol × Clear all
NCT03474614 2024-04-19

Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

St. Joseph's Hospital and Medical Center, Phoenix

Phase 2 Terminated
4 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

NCT03589014 2022-02-25

Treat_CCM

Mario Negri Institute for Pharmacological Research

Phase 2 Completed
71 enrolled
CNS

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡